Allogene Therapeutics Inc.’s decision to ditch the program for its lead CD19-directed allogeneic CAR-T cell therapy candidate, cemacabtagene ansegedleucel (cema-cel), in third-line large B-cell lymphoma (LBCL) and instead move it into the frontline consolidation setting opens up a much less saturated market opportunity, but some analysts have also pointed out that it could take a long time to bear fruit.
Allogene’s Cema-Cel Goes Express As Company Shifts To First-Line LBCL
Autoimmune CAR-T Could Sidestep Lymphodepletion
The allogeneic CAR-T developer announced a significant shift in its business strategy to develop its lead candidate in first-line consolidation of LBCL as the third-line disease setting becomes saturated.
More from Strategy
More from Business
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.